Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2010. The report serves as a notification of a directorate change and confirms compliance with Listing Rule 9.6.13R.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance update rather than a financial results report.
Material Changes
The primary material change disclosed is the appointment of Simon Dingemans as Executive Director and Chief Financial Officer Designate, effective January 4, 2011. The company confirms no further disclosures are required regarding this appointment.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Simon Dingemans is appointed as Executive Director and Chief Financial Officer Designate.
- The effective date for the new appointment is January 4, 2011.
- The company has confirmed no additional disclosures are necessary under Listing Rule 9.6.13R.
- This filing does not contain financial performance data for the period.